Letter to the Editor

Malek B Hannouf; Dale Muzzey; Ralf Kronenwett; Johnathan M Lancaster

doi:10.2217/cer-2019-0050

Letter to the Editor

J Comp Eff Res. 2019 Nov;8(15):1257-1259. doi: 10.2217/cer-2019-0050. Epub 2019 Nov 19.

Authors

Malek B Hannouf¹, Dale Muzzey², Ralf Kronenwett³, Johnathan M Lancaster²

Affiliations

¹ Department of Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, N6A 3K7.
² Myriad Genetics, Inc., Salt Lake City, UT 84108, USA.
³ Myriad International GmbH, Cologne, Germany.

PMID: 31741394
DOI: 10.2217/cer-2019-0050

No abstract available

Keywords: breast cancer; chemotherapy de-escalation; comparative effectiveness research; economics; evidence-based practice; meta-analysis; multi-gene assays.

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms*
Estrogens
Humans

Substances

Estrogens